June 16, 2024
Rising Uterine Fibroids Treatment Drugs Market

Uterine Fibroids Treatment Drugs Market Witness High Growth due to Rising Demand for Minimally Invasive Procedures

Uterine fibroids are non-cancerous growths that develop in or around the uterus. Uterine fibroids treatment drugs help reduce fibroid-related symptoms like heavy menstrual bleeding, anemia and pelvic pain. These drugs include gonadotropin-releasing hormone agonists (GnRH agonists), oral contraceptives and progestin-releasing intrauterine devices. The increased adoption of minimally invasive procedures like uterine artery embolization and magnetic resonance guided focused ultrasound surgery for fibroid treatment over hysterectomies is projected to drive the uterine fibroids treatment drugs market.

The Global uterine fibroids treatment drugs market is estimated to be valued at US$ 1.87 Bn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the uterine fibroids treatment drugs are Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics.
The key opportunities in the market include rising awareness about minimally invasive treatment options and new product launches. Technological advancements like the development of focused ultrasound therapy and magnetic resonance guided focused ultrasound surgery are expected to boost the market growth.

Market Drivers

The rising geriatric female population prone to uterine fibroids and the availability of reimbursement for minimally invasive fibroid Uterine Fibroids Treatment Drugs Market Size procedures in developed countries are expected to propel the market forward. Additionally, increasing health expenditure and adoption of sedentary lifestyle resulting in delayed childbearing is also fueling the prevalence of uterine fibroids and consequent demand for treatment drugs.

Current Challenges In The Uterine Fibroids Treatment Drugs Market:

The uterine fibroids treatment drugs market is facing several challenges currently. One of the major challenges is the lack of approved drugs specifically for uterine fibroids. Most of the drugs available are off-label usage of other drugs. This limits the treatment options for patients and doctors. Another challenge is the adverse side effects associated with the existing drugs. The drugs have potential side effects like hot flashes, night sweats, loss of libido etc. This limits compliance. Fibroid recurrence is also a major problem. Complete removal or shrinkage of fibroids is difficult with drugs alone. More effective and targeted treatment options are needed in the market.

SWOT Analysis

Strength: Growing research into drug therapies specifically for fibroids; established players are investing to develop novel targeted drugs.

Weakness: Limited approved treatment options currently; existing drugs have potential side effects.

Opportunity: Untapped growth potential in developing countries; development of more effective and tolerable targeted therapies.

Threats: High R&D costs impact drug price; regulatory approval hurdles for new drugs.

Geographical Regions

North America currently accounts for the largest share of the uterine fibroids treatment drugs market in terms of value owing to high healthcare spending and established pharmaceutical industry. The United States represents the major market within North America. Europe is the second largest regional market driven by growing awareness and availability of treatments. Asia Pacific region is anticipated to be the fastest growing market during the forecast period owing to rising healthcare investment and increasing diagnosis of uterine fibroids in countries like India and China.

The fastest growing regional market for uterine fibroids treatment drugs is anticipated to be Asia Pacific over the forecast period from 2024 to 2031. This is attributed to factors like increasing healthcare spending, growing women population, rising awareness about uterine fibroids and its treatment options, and presence of emerging economics with huge patient population like India and China offering significant growth opportunities.

*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.